Safety and Efficacy of Sintilimab and Anlotinib as First Line Treatment for Advanced Hepatocellular Carcinoma (KEEP-G04): A Single-Arm Phase 2 Study

PURPOSE: Immune checkpoint inhibitors plus antiangiogenic tyrosine kinase inhibitors may offer a first-line treatment for advanced hepatocellular carcinoma (HCC). In this phase 2 trial [registered with clinicaltrials.gov (NCT04052152)], we investigated the safety and efficacy of first-line anti-PD-1...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Xiaofeng, Li, Wei, Wu, Xiaofeng, Zhao, Fengjiao, Wang, Deqiang, Wu, Hao, Gu, Yanhong, Li, Xiao, Qian, Xiaofeng, Hu, Jun, Li, Changxian, Xia, Yongxiang, Rao, Jianhua, Dai, Xinzheng, Shao, Qianwen, Tang, Jie, Li, Xiangcheng, Shu, Yongqian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9197581/
https://www.ncbi.nlm.nih.gov/pubmed/35712486
http://dx.doi.org/10.3389/fonc.2022.909035

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9197581/
https://www.ncbi.nlm.nih.gov/pubmed/35712486
http://dx.doi.org/10.3389/fonc.2022.909035

Ejemplares similares